Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

The effect of hypnosis on pain and peripheral blood flow in sickle-cell disease: a pilot study.

Bhatt RR, Martin SR, Evans S, Lung K, Coates TD, Zeltzer LK, Tsao JC.

J Pain Res. 2017 Jul 14;10:1635-1644. doi: 10.2147/JPR.S131859. eCollection 2017.

2.

Randomized trial of hypnosis as a pain and symptom management strategy in adults with sickle cell disease.

Wallen GR, Middleton KR, Ames N, Brooks AT, Handel D.

Integr Med Insights. 2014 Nov 3;9:25-33. doi: 10.4137/IMI.S18355. eCollection 2014.

3.

Individuals with sickle cell disease have a significantly greater vasoconstriction response to thermal pain than controls and have significant vasoconstriction in response to anticipation of pain.

Khaleel M, Puliyel M, Shah P, Sunwoo J, Kato RM, Chalacheva P, Thuptimdang W, Detterich J, Wood JC, Tsao J, Zeltzer L, Sposto R, Khoo MCK, Coates TD.

Am J Hematol. 2017 Nov;92(11):1137-1145. doi: 10.1002/ajh.24858. Epub 2017 Aug 17.

4.

Biophysical markers of the peripheral vasoconstriction response to pain in sickle cell disease.

Chalacheva P, Khaleel M, Sunwoo J, Shah P, Detterich JA, Kato RM, Thuptimdang W, Meiselman HJ, Sposto R, Tsao J, Wood JC, Zeltzer L, Coates TD, Khoo MCK.

PLoS One. 2017 May 24;12(5):e0178353. doi: 10.1371/journal.pone.0178353. eCollection 2017.

5.

Hospitalist management of vaso-occlusive pain crisis in patients with sickle cell disease using a pathway of care.

Allen Liles E, Kirsch J, Gilchrist M, Adem M.

Hosp Pract (1995). 2014 Apr;42(2):70-6. doi: 10.3810/hp.2014.04.1105.

PMID:
24769786
6.

Magnetic Resonance Imaging Assessment of Kidney Oxygenation and Perfusion During Sickle Cell Vaso-occlusive Crises.

Deux JF, Audard V, Brugières P, Habibi A, Manea EM, Guillaud-Danis C, Godeau B, Galactéros F, Stehlé T, Lang P, Grimbert P, Audureau E, Rahmouni A, Bartolucci P.

Am J Kidney Dis. 2017 Jan;69(1):51-59. doi: 10.1053/j.ajkd.2016.07.027. Epub 2016 Sep 20.

PMID:
27663041
7.
8.

Autonomic responses to cold face stimulation in sickle cell disease: a time-varying model analysis.

Chalacheva P, Kato RM, Sangkatumvong S, Detterich J, Bush A, Wood JC, Meiselman H, Coates TD, Khoo MC.

Physiol Rep. 2015 Jul 14;3(7). pii: e12463. doi: 10.14814/phy2.12463. Epub 2015 Jul 14.

9.

Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review.

Sins JWR, Mager DJ, Davis SCAT, Biemond BJ, Fijnvandraat K.

Blood Adv. 2017 Aug 22;1(19):1598-1616. doi: 10.1182/bloodadvances.2017007211. eCollection 2017 Aug 22. Review.

10.

IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies.

Dampier CD, Smith WR, Wager CG, Kim HY, Bell MC, Miller ST, Weiner DL, Minniti CP, Krishnamurti L, Ataga KI, Eckman JR, Hsu LL, McClish D, McKinlay SM, Molokie R, Osunkwo I, Smith-Whitley K, Telen MJ; Sickle Cell Disease Clinical Research Network (SCDCRN).

Clin Trials. 2013 Apr;10(2):319-31. doi: 10.1177/1740774513475850.

11.

Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation.

Belhassen L, Pelle G, Sediame S, Bachir D, Carville C, Bucherer C, Lacombe C, Galacteros F, Adnot S.

Blood. 2001 Mar 15;97(6):1584-9.

12.

Mouse Models of Pain in Sickle Cell Disease.

Sagi V, Song-Naba WL, Benson BA, Joshi SS, Gupta K.

Curr Protoc Neurosci. 2018 Oct;85(1):e54. doi: 10.1002/cpns.54. Epub 2018 Sep 28.

PMID:
30265442
13.

Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.

Neri CM, Pestieau SR, Darbari DS.

Paediatr Anaesth. 2013 Aug;23(8):684-9. doi: 10.1111/pan.12172. Epub 2013 Apr 9. Review.

PMID:
23565738
14.
15.

Thinking beyond sickling to better understand pain in sickle cell disease.

Darbari DS, Ballas SK, Clauw DJ.

Eur J Haematol. 2014 Aug;93(2):89-95. doi: 10.1111/ejh.12340. Epub 2014 May 16. Review.

16.

The role of the arginine metabolome in pain: implications for sickle cell disease.

Bakshi N, Morris CR.

J Pain Res. 2016 Mar 30;9:167-75. doi: 10.2147/JPR.S55571. eCollection 2016. Review.

17.

Self-hypnosis training as an adjunctive treatment in the management of pain associated with sickle cell disease.

Dinges DF, Whitehouse WG, Orne EC, Bloom PB, Carlin MM, Bauer NK, Gillen KA, Shapiro BS, Ohene-Frempong K, Dampier C, Orne MT.

Int J Clin Exp Hypn. 1997 Oct;45(4):417-32.

PMID:
9308268
18.

A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease.

Kutlar A, Ataga KI, McMahon L, Howard J, Galacteros F, Hagar W, Vichinsky E, Cheung AT, Matsui N, Embury SH.

Am J Hematol. 2012 May;87(5):536-9. doi: 10.1002/ajh.23147. Epub 2012 Apr 10. Review.

19.

Markers of endothelial dysfunction and leucocyte activation in Saudi and non-Saudi haplotypes of sickle cell disease.

Al Najjar S, Adam S, Ahmed N, Qari M.

Ann Hematol. 2017 Jan;96(1):141-146. doi: 10.1007/s00277-016-2823-7. Epub 2016 Sep 30.

PMID:
27686084
20.

Plasma PTX3 levels in sickle cell disease patients, during vaso occlusion and acute chest syndrome (data from Saudi population).

Elshazly SA, Heiba NM, Abdelmageed WM.

Hematology. 2014 Jan;19(1):52-9. doi: 10.1179/1607845413Y.0000000092. Epub 2013 Nov 25.

PMID:
23735470

Supplemental Content

Support Center